期刊文献+

面向未来:世界需要中医药 被引量:13

For the future: the world needs Traditional Chinese Medicine
下载PDF
导出
摘要 随着疾病谱的改变和人们生活方式的转变,医学界面临巨大挑战,慢性复杂性疾病占主体,消耗了大量医疗资源,西方发达国家也不堪重负。"看病难、看病贵"已成为全球医疗问题。在有限卫生资源条件下,要满足13亿人的健康需求,必须走适合国情的中国式道路,用"中国式办法"解决好医改这个世界性难题。简单讲,中国式办法离不开中医药。在2015年博鳌论坛上,作者从医学界的挑战、中医药的优势特色、中医药发展与科技和中医药国家战略四个方面,阐述了世界需要中医药。我们也相信,中医药事业的发展将为解决好世界医改难题做出贡献。 Along with the change of disease spectrum and people's life style, medicine is facing great challenge: chronic complex diseases have become the main body of diseases which consumed a lot of medical resources. Western developed countries are also overwhelmed. Difficulty and high cost in hospital has become a global medical problem. With limited health resources to serve 1.3 billion people, we should take Chinese road according to the condition at present and solve the problem of medical reform by China-style method. Generally, China-style method can't do without traditional Chinese medicine. In the Boao Forum, the author elaborated that the world needs Chinese medicine from four aspects, including challenges in medicine, characteristics and advantages of Chinese medicine, Chinese medicine development depending on technology and the national strategies of Chinese medicine. We believe that the development of Chinese medicine will contribute a lot to solving the problems of health care reform worldwide.
作者 张伯礼
出处 《医学争鸣》 CAS 北大核心 2016年第1期1-4,共4页 Negative
关键词 中医药 医改 博鳌论坛 Chinese medicine reform of health system Boao Forum for Asia
  • 相关文献

参考文献11

  • 1张伯礼.主编新年寄语[J].中医杂志,2013,54(1):1-2. 被引量:6
  • 2张伯礼.系统生物学将推动中药复杂体系的深入研究[J].中国天然药物,2009,7(4):241-241. 被引量:7
  • 3Wang C, Cao B, Liu QQ, et al. Oseltamivir compared withthe Chinese traditional therapy maxingshigan-yinqiaosanin the treatment of HjNj influenza: a randomized trialfj].Ann Intern Med, 2011, 155(4):217-225. 被引量:1
  • 4Li X, Zhang J, Huang J, et al. A multicenter, randomized,double-blind, parallel-group,placebo-controlled study ofthe effects of qili qiangxin capsules in patients with chronicheart failure[J]. J Am Coll Cardiol, 2013, 62(12):1065-1072. 被引量:1
  • 5Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qi drippingpills for the secondary prevention of myocardial infarction:a randomised clinical trial[J]. Evid Based ComplementAltemat Med, 2013, 2013:738391. 被引量:1
  • 6Phase II multi-center study of T89 to treat chronic stableangina (T89 phase 2)[EB/OL].(2012-12-10) [2015-06].https://www.clinicaltrials.gov/ct2/show/NCT00797953?term=tasly&rank=6. 被引量:1
  • 7Phase III trial of Dantonic? (T89) Capsule to prevent and treatstable angina (CAESA) [EB/OL]. (2015-05-19) [2015-06].https://www.clinicaltrials.gov/ct2/show/NCT01659580?term=tasly&rank=3. 被引量:1
  • 8Assess the antifibrotic activity of Fuzheng Huayu in chronichepatitis C patients with hepatic fibrosis[EB/OL]. (2014-06-18)[2015-06]. https://www.clinicaltrials.gov/ct2/show/study/NCT00854087?cond=hepatic+fibrosis&spons=shanghai&rank=3. 被引量:1
  • 9Efficacy and safety study of lipid-lowering effects ofXueZhiKang (XZK) in patients with hyperlipidemia[EB/0L].(2014-07-22) [2015-06]. https://clinicaltrials.gov/ct2/show/NCT01327014?term=xuezhikang&rank=3. 被引量:1
  • 10Gruenwald J. The global herbs & botanicals market[EB/OL].[2015-06]. https://www.otciq.com/otciq/ajax/show FinancialReportById.pdf?id=27951. 被引量:1

共引文献12

同被引文献214

引证文献13

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部